Home >> Research Area >>Proteases/Proteasome>>DPP-4>> Alogliptin (SYR-322)

Alogliptin (SYR-322)

DPP-4 inhibitor,potent and highly selective CAS# 850649-61-5

Alogliptin (SYR-322)

Catalog No. BCC2113----Order now to get a substantial discount!

Product Name & Size Price Stock
Alogliptin (SYR-322): 5mg $17 In Stock
Alogliptin (SYR-322): 10mg Please Inquire In Stock
Alogliptin (SYR-322): 20mg Please Inquire Please Inquire
Alogliptin (SYR-322): 50mg Please Inquire Please Inquire
Alogliptin (SYR-322): 100mg Please Inquire Please Inquire
Alogliptin (SYR-322): 200mg Please Inquire Please Inquire
Alogliptin (SYR-322): 500mg Please Inquire Please Inquire
Alogliptin (SYR-322): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Alogliptin (SYR-322)

Number of papers citing our products

Chemical structure

Alogliptin (SYR-322)

3D structure

Chemical Properties of Alogliptin (SYR-322)

Cas No. 850649-61-5 SDF Download SDF
PubChem ID 11450633 Appearance Powder
Formula C18H21N5O2 M.Wt 339.39
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Alogliptin,SYR322
Solubility >14.8mg/mL in DMSO
Chemical Name 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
SMILES CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
Standard InChIKey ZSBOMTDTBDDKMP-OAHLLOKOSA-N
Standard InChI InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Alogliptin (SYR-322)

DescriptionAlogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
TargetsDPP-4    
IC50< 10 nM     

Protocol

Cell experiment: [1]

Cell lines

U937 histiocyte

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

5 nM, 48h, inhibited cell proliferation 1 nM, 48h, inhibited MMP-1 secretion

Applications

Alogliptin inhibited cell proliferation by 53% at concentration of 5 nM. At 1 nM, alogliptin inhibited MMP-1 secretion significantly, suggesting that the inhibitory effect of alogliptin on MMP is not associated with that on cell proliferation.

Animal experiment : [2]

Animal models

Zucker fa/fa rats

Dosage form

Eight-week-old male Zucker fa/fa rats were divided into 5 groups based on body weight and fasting plasma glucose levels and administered vehicle alone (0.5% carboxymethylcellulose) or alogliptin at 0.3, 1, 3, or 10 mg/kg by single bolus oral gavage (5 ml/kg dose volume). At 30 min postdose, rats were given a glucose solution (1 g/kg, 2ml/kg dose volume). Blood glucose concentrations were analyzed up to 90min after glucose load using the Accu-Chek glucometer and plasma insulin concentrations were analyzed up to 60 min after glucose load using an insulin ELISA kit.

Application

Early-phase insulin secretion was increased after a single dose of alogliptin compared with vehicle alone. Alogliptin increased about 1.5, 1.5, and 1.8 fold for the 0.3, 1, and 3 mg/kg doses. Significant decreases in blood glucose excursion were observed for all alogliptin doses compared with vehicle alone after an oral glucose load. Mean baseline-adjusted blood glucose AUC0–90 min was decreased by approximately 31%, 37%, and 41% for the 0.3, 1, and 3 mg/kg doses, respectively.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Ta N N, Li Y, Schuyler C A, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis, 2010, 213(2): 429-435.

[2] Lee B, Shi L, Kassel D B, et al. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. European journal of pharmacology, 2008, 589(1): 306-314.

Alogliptin (SYR-322) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Alogliptin (SYR-322) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Alogliptin (SYR-322)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.9465 mL 14.7323 mL 29.4646 mL 58.9293 mL 73.6616 mL
5 mM 0.5893 mL 2.9465 mL 5.8929 mL 11.7859 mL 14.7323 mL
10 mM 0.2946 mL 1.4732 mL 2.9465 mL 5.8929 mL 7.3662 mL
50 mM 0.0589 mL 0.2946 mL 0.5893 mL 1.1786 mL 1.4732 mL
100 mM 0.0295 mL 0.1473 mL 0.2946 mL 0.5893 mL 0.7366 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Research Update of Alogliptin (SYR-322)

1. Alogliptin: Safety, Efficacy, and Clinical Implications. J Pharm Pract. 2014 Feb 13. [Epub ahead of print]
Abstract
Alogliptin is not only an inhibitor of DPP-4 that raises postprandial levels of glucagon-like peptide 1 resulting in insulin secretion and glucose homeostasis but also a safe and tolerable anti-diabetic agent showing a significant reduction in HdA1c when used alone or with other anti-diabetic agents.
2. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacother. 2013 Nov;47(11):1532-9. doi: 10.1177/1060028013504076.
Abstract
Alogliptin, a DPP-4 inhibitor, has been reviewed for its pharmacology, pharmacokinetics, safety and efficacy in the managment of T2DM.
3. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Jul;15(7):668-73. doi: 10.1111/dom.12093. Epub 2013 Apr 4.
Abstract
The cardiovascular profile of alogliptin, a DPP-4 inhibitor, has been evaluated due to increased CV risk associated with the treatment of type 2 diabetes.
4. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3;369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.
Abstract
Alogliptin, a DPP-4 inhibitor, has been assessed for its cardiovascular outcomes in patients with type 2 diabetes and a recent acute coronary syndrome.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Alogliptin (SYR-322)

Alogliptin (also known as SYR-322), is a novel, orally-available and highly selective quinazolinone-based inhibitor of dipeptidyl peptidase-4 (DPP-4), a serine aminopeptidase catalyzing the cleavage of peptides, that potently inhibits human DPP-4 in vitro with 50% inhibition concentration IC50 value of 6.9 nM and barely exhibits any inhibition towards the closely related serine proteases, including DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidas and tryptase (IC50 > 100,000 nM for all). Alogliptin prevents DPP-4-catalyzed degradation of GLP-1 and GIP, which regulate concentrations of blood glucose by stimulating glucose-dependent insulin secretion, and hence is being investigated in the treatment of type 2 diabetes.

Reference

Bumsup Lee, Lihong Shi, Daniel B. Kassel, Tomoko Asakawa, Koji Takeuchi and Ronald J. Christopher. Pharmacokinetic, pharmacodynamics, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. European Journal of Pharmacology 589 (2008) 306-314

Featured Products
New Products
 

References on Alogliptin (SYR-322)

A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.[Pubmed:19427871]

Life Sci. 2009 Jul 17;85(3-4):122-6.

AIMS: Loss of efficacy over time or secondary failure occurs somewhat often and remains a major concern of sulfonylurea (SU) therapy. In this study, we investigated the benefits of alogliptin, an oral, potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, in a rat model exhibiting SU secondary failure. MAIN METHODS: Neonatally streptozotocin-induced diabetic rats (N-STZ-1.5 rats), a non-obese model of type 2 diabetes, were used in these studies. The effects of alogliptin on DPP-4 activity and glucagon-like peptide 1 (GLP-1) concentration were determined by measuring their levels in plasma. In addition, the effects of alogliptin on an oral glucose tolerance test were investigated by using an SU secondary failure model. KEY FINDINGS: Alogliptin dose dependently suppressed plasma DPP-4 activity leading to an increase in the plasma active form of GLP-1 and improved glucose excursion in N-STZ-1.5 rats. Repeated administration of glibenclamide resulted in unresponsiveness or loss of glucose tolerance typical of secondary failure. In these rats, alogliptin exhibited significant improvement of glucose excursion with significant increase in insulin secretion. By contrast, glibenclamide and nateglinide had no effect on the glucose tolerance of these rats. SIGNIFICANCE: The above findings suggest that alogliptin was effective at improving glucose tolerance and therefore overcoming SU induced secondary failure in N-STZ-1.5 rats.

Description

Alogliptin (SYR-322 free base) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.

Keywords:

Alogliptin (SYR-322),850649-61-5,Alogliptin,SYR322,Natural Products,DPP-4, buy Alogliptin (SYR-322) , Alogliptin (SYR-322) supplier , purchase Alogliptin (SYR-322) , Alogliptin (SYR-322) cost , Alogliptin (SYR-322) manufacturer , order Alogliptin (SYR-322) , high purity Alogliptin (SYR-322)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: